Neuroprotection for Ischemic Stroke: Two Decades of Success and Failure

NeuroRx

Volumn 1, Issue 1, 2004, Pages 36-45

  Cheng, Yu Dennis ^a   Al Khoury, Lama ^a   Zivin, Justin A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anti inflammatory agents; free radical scavengers; glutamate antagonists; ion channel blocks; neural stem cells; Neuroprotection trials; neurotrophic factors

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ALTEPLASE; ANTIINFLAMMATORY AGENT; APTIGANEL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CITICOLINE; DIAZEPAM; DISUFENTON SODIUM; EBSELEN; ELIPRODIL; FLUNARIZINE; FOSPHENYTOIN SODIUM; GANGLIOSIDE GM1; GLUTAMATE RECEPTOR ANTAGONIST; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; MAGNESIUM SULFATE; NALMEFENE; NEUROTROPHIC FACTOR; NEUTROPHIL INHIBITORY FACTOR; NIMODIPINE; PHENYTOIN; PLACEBO; REPINOTAN; ROVELIZUMAB; SCAVENGER; TIRILAZAD; UNINDEXED DRUG; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INDUCED HYPOTHERMIA; META ANALYSIS; NEURAL STEM CELL; NEUROPROTECTION; PATIENT SELECTION; REPERFUSION; STROKE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; BRAIN; DRUG EFFECT; REVIEW; VASCULARIZATION;

ANIMALS; BRAIN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 19544376511     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.1.36     Document Type: Article

References (93)

1. American Stroke Association. Heart Disease and Stroke Statistics-2003 Updat (2003), American Heart Association, Dallas
2. Marshall J., Duffin K., Green A., and Ridley R. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32 (2001) 190-198
3. Shimizu-Sasamata M., Kano T., Rogowska J., Wolf G., Moskowitz M., and Lo E. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Stroke 29 (1998) 2141-2148
4. Lapchak P., et al. A novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 33 (2002) 2279-2284
5. Steen P., Newberg L., Milde J., and Michenfelder J. Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog. J Cereb Blood Flow Metab 3 (1983) 38-43
6. Kidwell C., Liebeskind D., Starkman S., and Saver J. Trends in acute ischemic stroke trial through the 20th century. Stroke 32 (2001) 1349-1359
7. Zivin J., and Grotta J. Animal stroke models: they are relevant to human disease. Stroke 21 (1990) 981-983
8. Gorelick P. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls. Lancet 355 (2000) 1925-1926
9. Morgenstern L. What have we learned from clinical neuroprotective trials?. Neurology 57 (2001) S45-S47
10. Gladstone D., Black S., and Hakim A. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002) 2123-2136
11. Guyot L., Diaz F., O'Regan M., Song D., and Phillis J. Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. Neurosci Lett 299 (2001) 37-40
12. Boast C., Gerhardt B., Pastor G., Lehmann J., Etienne P., and Liebman J. The N-methyl-d-aspartate antagonist CGS19755 and CPP reduce ischemic brain damage in gerbils. Brain Res 442 (1988) 345-348
13. Gotti B., Duverger D., Bertin J., Carter C., Dupont R., Frost J., et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. 1. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther 247 (1988) 1211-1221
14. O'Neill M., Hicks C., and Ward M. Neuroprotective effects of 7-nitroindazole in gerbil model of global cerebral ischemia. Eur J Pharmacol 310 (1996) 115-122
15. Patat A., Molinjier P., Hergueta T., Brohier S., Zieleniuk I., Danjou P., et al. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist. Int Clin Psychopharmacol 9 (1994) 155-162
16. Aronowski J., Ostrow P., Samways E., Strong R., Zivin J., and Grotta J. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke 25 (1994) 2235-2240
17. Cohen R., Hasegawa Y., and Fisher M. Effects of a novel NMDA receptor antagonist on experimental stroke quantitatively assessed by spectral EEG and infarct volume. Neurol Res 16 (1994) 443-448
18. Muir K. New experimental data on the efficacy of pharmacological magnesium infusions in cerebral infarcts [abstract]. Magnes Res 11 (1998) 43-56
19. Saver JL, Kidwell CS, FAST-MAG Trial Group. The Field Administration of Stroke Therapy-Magnesium (FAST-MAG) phase 3 trial. Paper presented at The American Heart Association 27th International Stroke Conference, Ongoing clinical trial session, 2002
20. Clark W., Madden K., Rothlein R., and Zivin J. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg 75 (1991) 623-627
21. Zhang R., Chopp M., Jiang N., Tang W., Prostak J., Manning A., et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 26 (1995) 1438-1443
22. Jiang N., Chopp M., and Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res 788 (1998) 25-34
23. Ohta K., Graf R., Rosner G., and Heiss W. Calcium ion transients in peri-infarct depolarizations may deteriorate ion homeostasis and expand infarction in focal cerebral ischemia in cats. Stroke 32 (2001) 535-543
24. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 23 (1992) 3-8
25. Mohr J., Ogogozo J., and Harrison M. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 4 (1994) 197-203
26. Horn J., de Haan R., Vermeulen M., and Limburg M. Very early nimodipine use in stroke (VENUS). Stroke 32 (2001) 461-465
27. McLean M., and MacDonald R. Multiple action of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 227 (1983) 779-789
28. Ferrendelli J., and Danials-McQueen S. Comparative actions of phenytoin and other antiepileptic drugs on potassium-and veratridine-stimulated calcium uptake in synaptosomes. J Pharmacol Exp Ther 220 (1983) 29-34
29. Bebin M., and Bleck T. New anticonvulsant drugs: focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs 48 (1994) 153-171
30. Gribkoff V., Starrett Jr. J., Dworetzky S., et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 7 (2001) 471-477
31. Cheng Y., and Sun A. The biomechanisms of kainate-induced neurotoxicity involved in oxidative insult. Neurochemical Res 19 (1994) 1557-1564
32. Lapchak P., Chapman D., and Zivin J. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 32 (2001) 147-153
33. Haley E., Kassell N., Apperson-Hansen C., Maile M., and Alves W. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 86 (1997) 467-474
34. Haley Jr. E. High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II investigators. Stroke 29 (1998) 1256-1257
35. D'Orlando K., and Sandage Jr. B. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol Res 17 (1995) 281-284
36. Schabitz W., Ali F., Irie K., Sandage Jr. B., Locke K., and Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke 30 (1999) 427-432
37. Clark W., Warach S., Pettigrew L., Gammans R., and Sabounjian L. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 49 (1998) 671-678
38. Zhao Z., Cheng M., Maples K., Ma J., and Buchan A. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 909 (2001) 46-50
39. Marshall J., Duffin K., Green A., and Ridley R. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32 (2001) 190-198
40. Lapchak P., Araujo D., Song D., Wei J., and Zivin J. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33 (2002) 1411-1415
41. Peeling J., Del Bigio M., Corbett D., Green A., and Jackson D. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 40 (2001) 433-439
42. Lees K., Sharma A., Barer D., Ford G., Kostulas V., Cheng Y., et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32 (2001) 675-680
43. Evans J., Feuerlein W., Glatt M., Kanowski S., and Scott D. Chlomethiazole 25 years: recent developments and historical perspectives. Acta Psychiatr Scand Suppl 73 Suppl 327 (1986) 198
44. Green A. Clomethiazole (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy. Pharmacol Ther 80 (1998) 123-147
45. Lyden P., Jacoby M., Schim J., Albers G., Mazzeo P., Ashwood T., et al. The clomethiazole acute stroke study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology 57 (2001) 1199-1205
46. Alessandri B., Tsuchida E., and Bullock R. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res 845 (1999) 232-235
47. Cheng Y., Deshmukh M., D'Costa A., Demaro J., Gidday J., Shah A., et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest 101 (1998) 1992-1999
48. Endres M., Namura S., Shimizu-Sasamata M., Waeber C., Zhang L., Gomez-Isla T., et al. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 18 (1998) 238-247
49. Chen J., Li Y., Wang L., Lu M., and Chopp M. Caspase inhibition by Z-VAD increases the survival of grafted bone marrow cells and improves functional outcome after MCAo in rats. J Neurol Sci 199 (2002) 17-24
50. Yum S., and Faden A. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 47 (1990) 277-281
51. Graham S., Shimizu H., Newman A., Weinstein P., and Faden A. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia. Brain Res 632 (1993) 346-350
52. Clark W., Raps E., Tong D., and Kelly R. Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 31 (2000) 1234-1239
53. Leon A., Lipartiti M., Seren M., Lazzaro A., Mazzari S., Koga T., et al. Hypoxic-ischemic damage and the neuroprotective effects of GM1ganglioside. Stroke 21 Suppl 11 (1990) 11195-11197
54. Carolei A., Fieschi C., Bruno R., and Toffano G. Monosialoganglioside GM1 in cerebral ischemia. Cerebrovasc Brain Metab Rev 3 (1991) 134-157
55. Argentino C., Sacchetti M., Toni D., Savoini G., D'Arcangelo E., Erminio F., et al. GM1 ganglioside therapy in acute ischemic stroke: Italian Acute Stroke Study-Hemodilusion + drug. Stroke 20 (1989) 1143-1149
56. Jessell T., and Sanes J. The generation and survival of nerve cells. In: Kandel E., Schwartz J., and Jessell T. (Eds). Principles of neural science (2000), McGraw-Hill, New York 1041-1062
57. Zhang Y., and Pardridge W. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 32 (2001) 1378-1384
58. Wen T., Matsuda S., Yoshimura T., Kawabe T., and Sakanaka M. Ciliary neurotrophic factor prevent ischemic-induced learning disability and neuronal loss in gerbils. Neurosci Lett 191 (1995) 55-58
59. Abe K. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab 20 (2000) 1393-1408
60. Holtzman D., Sheldon R., Cheng Y., Jaffe W., and Ferriero D. NGF protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 39 (1996) 114-122
61. Cheng Y., Gidday J., Yan Q., Shah A., and Holtzman D. Marked age-dependent neuroprotection by brain derived neurotrophic factor against neonatal hypoxic-ischemic brain injury. Ann Neurol 41 (1997) 521-529
62. Rosenblatt S., Irikura K., Caday D., Finklestein S., and Moskowitz M. Basic fibroblast growth factor (bFGF) dilates rat pial arterioles. J Cereb Blood Flow Metab 14 (1994) 70-74
63. Cuevas P., Carceller F., Ortega S., et al. Hypotensive activity of fibroblast growth factor. Science 254 (1991) 1208-1210
64. Fisher M., Meadows M.-E., Do T., et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent cerebral ischemia in rats. J Cereb Blood Flow Metab 15 (1995) 953-959
65. Jiang N., Finklestein S., Do T., Caday C., Charette M., and Chopp M. Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduced infarction volume in a model of focal cerebral ischemia/reperfusion in the rat. J Neurol Sci 139 (1996) 173-179
66. Reynolds B., and Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255 (1992) 1707-1710
67. Gould E., Reeves A., Graziano M., and Gross C. Neurogenesis in the neocortex of adult primates. Science 286 (1999) 548-552
68. Takagi Y., Nozaki K., Takahashi J., Ishikawa M., and Hashimoto N. Proliferation of neuronal precursor cells in the dentate gyrus is accelerated after transient forebrain ischemia in mice. Brain Res 831 (1999) 283-287
69. Nakatomi H., Kuriu T., Okabe S., Yamamoto S., Hantano O., Kawahara N., et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 110 (2002) 429-441
70. Li Y., Chen J., and Chopp M. Cell proliferation and differentiation from ependymal, subependymal and choroid plexus cells in response to stroke in rats. J Neurol Sci 193 (2002) 137-146
71. Modo M., Stroemer P., Tang E., Patel S., and Hodges H. Effects of implantation site of stem cell grafts on behavioral recovery from stroke damage. Stroke 33 (2002) 2270-2278
72. Woodbury D., Schwarz E., Prockop D., and Black I. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 61 (2000) 364-370
73. Li Y., Chen J., Chen X., Wang L., Gautam S., Xu Y., et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 59 (2002) 514-523
74. Kondziolka D., Wechsler L., Goldstein S., Meltzer C., Thulborn K., Gebel J., et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology 55 (2000) 565-569
75. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 346 (2002) 549-556
76. Wang Y., Lim L., Levi C., Heller R., and Fisher J. Influence of admission body temperature on stroke mortality. Stroke 31 (2000) 404-409
77. Krieger D., De Georgia M., Abou-Chebl A., Andrefsky J., Sila C., Katzan I., et al. Cooling for acute ischemic brain damage (COOL AID). Stroke 32 (2001) 1847-1854
78. Georgiadis D., Schwarz S., Kollmar R., and Schwab S. Endovascular cooling for moderate hypothermia in patients with acute stroke: first results of a novel approach. Stroke 32 (2001) 2550-2553
79. Dewar D., Yam P., and McCulloch J. Drug development for stroke: importance of protecting cerebral white matter. Eur J Pharmacol 375 (1999) 47-50
80. Hunter A., Mackay K., and Roger D. To what extent have functional studies of ischemia in animals been useful in the assessment of potential neuroprotective agents?. Trends Pharmacol Sci 19 (1998) 59-66
81. Duncan P., Jorgensen H., and Wade D. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 31 (2000) 1429-1438
82. Demchuk A., and Buchan A. Predictors of stroke outcome. Neurol Clin 18 (2001) 455-473
83. Grotta J. Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside: the Feinberg lecture. Stroke 30 (1999) 1722-1728
84. Zivin J. Factors determining the therapeutic window for stroke. Neurology 50 (1998) 599-603
85. Du C., Hu R., Csernansky C., Hsu C., and Choi D. Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis?. J Cereb Blood Flow Metab 16 (1996) 195-201
86. Jonas A., Aiyagari V., Vieira D., and Figueroa M. The failure of neuronal protective agents versus the success of thromolysis for the treatment of ischemic stroke: the predictive value of animal models. Ann NY Acad Sci 939 (2001) 257-267
87. Dyker A., and Lees K. Duration of neuroprotective treatment for ischemic stroke. Stroke 29 (1998) 535-542
88. Malakoff D. Bayes offers a "new" way to make sense of numbers. Science 286 (1999) 1460-1464
89. Wilson L., Hareendran A., Grant M., Baird T., Schulz U., Muir K., et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified ranking scale. Stroke 33 (2002) 2243-2246
90. Tilley B., Marler J., Geller N., Lu M., Legler J., Brott T., et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Trial. Stroke 27 (1996) 2136-2142
91. Zivin J., and Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 48 (1991) 1235-1238
92. Bowes M., Rothlein R., Fagan S., and Zivin J. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 45 (1995) 815-819
93. Lyden P., Lonzo L., and Nunez S. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke. J Neurotrauma 12 (1995) 223-230